Recent developments in ovarian cancer screening

There has been growing interest in the possibility of screening for ovarian cancer. This article addresses papers published following a systematic review of all prospective ovarian cancer screening studies since 1998. In the past year, new markers have been reported and previous strategies have been refined. A randomized controlled trial of ovarian cancer screening has shown a survival benefit in women who developed ovarian cancer in the screened group. Although the results do not justify ovarian cancer screening in the general population, the data support the need for a larger randomized trial powered to assess the impact of screening on mortality.

[1]  N. Urban.  Screening for ovarian cancer , 1999, BMJ.

[2]  P. Pharoah,et al.  Screening for breast and ovarian cancer: the relevance of family history. , 1998, British medical bulletin.

[3]  M. Law,et al.  The importance of age in screening for cancer , 1999, Journal of medical screening.

[4]  R. Kryscio,et al.  The malignant potential of small cystic ovarian tumors in women over 50 years of age. , 1998, Gynecologic oncology.

[5]  Steven J Skates,et al.  Screening for ovarian cancer: a pilot randomised controlled trial , 1999, The Lancet.

[6]  I. Jacobs,et al.  The Role of CA 125 in Screening for Ovarian Cancer , 1998, The International journal of biological markers.

[7]  J. Chang-Claude,et al.  Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. , 1998, European journal of cancer.

[8]  D. Aoki,et al.  Clinical characteristics of a newly developed ovarian tumour marker, galactosyltransferase associated with tumour (GAT). , 1998, European journal of cancer.

[9]  D. Oram,et al.  A comparison of national cancer registry and direct follow-up in the ascertainment of ovarian cancer , 1999, British Journal of Cancer.

[10]  R. Bast,et al.  Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers , 1995, Cancer.

[11]  R. L. Baldwin,et al.  Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. , 1999, American journal of obstetrics and gynecology.

[12]  J. Canick,et al.  Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer. , 1997, Gynecologic oncology.

[13]  Usha Menon,et al.  Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening , 2000, BJOG : an international journal of obstetrics and gynaecology.

[14]  I. Jacobs,et al.  Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation , 1999, British Journal of Cancer.

[15]  P. Kenemans,et al.  CA 125: fundamental and clinical aspects. , 1999, Seminars in cancer biology.

[16]  M Markman,et al.  Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. , 1998, JAMA.

[17]  D. Parkin,et al.  The performance of screening tests for ovarian cancer: results of a systematic review , 1999, British journal of obstetrics and gynaecology.

[18]  T. Miyamoto,et al.  Bilateral Oophorectomy in Asymptomatic Women over 50 Years Old Selected by Ovarian Cancer Screening , 1999, Gynecologic and Obstetric Investigation.

[19]  C. Sohn,et al.  Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study. , 1998, Gynecologic oncology.